Our platform harnesses a combination of machine learning and computational modeling, to create an entirely new class of therapeutics, enabling a step-change in precision targeting of drug targets.
Current Status
We have raised almost $2M in funding from VC firms and private investors, hired an experienced top-tier oncology and neuroscience-focused research team, established a facility and production line for the development of pre-clinical assets for various indications, and achieved proof of concept for our platform.
Problem or Opportunity
Current medicines lack precision targeting, this reduces efficacy, results in clinical trial failures, and causes side-effects and suffering for patients.
Solution (product or service)
Crosshair has developed a precision drug targeting platform utilizing a blend of AI and a unique molecular scaffold. The platform enables the production of chain-like therapeutics capable of high precision targeting to specific organs and tissues. Essentially, we produce biological IP addresses, and the drug targets can be thought of as the servers we target.
Business model
Our business model is hybrid. We are focused on generating revenue from partnering on our platform with biotech and pharma. Additionally, we are actively raising capital from VC firms and other investors. These sources fo capital will together provide the opportunity to advance our therapies through clinical trials independently or in partnership with pharma, elevating Crosshair's platform to clinical validation.
